Nowadays, a growing body of evidence implicates intratumoral heterogeneity, EMT, and increased ZEB1 levels as among the main drivers of therapy resistance, exemplified by EMT-induced docetaxel resistance in prostate cancer (Hanrahan et al., 2017), gemcitabine resistance in pancreatic cancer (Wang et al., 2017), and multiple types of resistance within various malignancies (Shibue and Weinberg, 2017; Cui et al., 2018; Zhang et al., 2018; Orellana-Serradell et al., 2019). The gene discussed is ZEB1; the disease is Familial prostate cancer.